Under the agreement, Galapagos has acquired all of Sareum’s ongoing services contracts relating to structure-based drug discovery, the Crystal Bank, a fragment screening library and the specialized equipment needed to perform structure-based drug discovery.
According to Galapagos, the acquired technology will be incorporated within BioFocus DPI’s capabilities in screening and medicinal chemistry, and will complement its services offering. A team of five Sareum employees will join BioFocus DPI (Chesterford Park, Saffron Walden, UK) and continue to operate the platform, securing a smooth transition of the business.
Tim Mitchell, CEO of Sareum Holdings, said: “I am confident that the acquisition of Sareum’s expertise in structure-based drug discovery services will further enhance BioFocus DPI’s leading position in global drug discovery service provision.”